Based on the fact that more significant tumour growth inhibition was achieved with the NGR-modified compound both in the LLC and Colo 205 tumour-bearing mice, NGR peptides could be pioneering in the targeted delivery of anti-cancer drugs. This evidence concerns the gene RTN4R and neoplasm.